Free Trial
LON:MPH

Mereo BioPharma Group plc (MPH.L) (MPH) Share Price, News & Analysis

Mereo BioPharma Group plc (MPH.L) logo

About Mereo BioPharma Group plc (MPH.L) Stock (LON:MPH)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
26.50
26.50
52-Week Range
N/A
Volume
49,264 shs
Average Volume
333,975 shs
Market Capitalization
£89.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

Remove Ads
Receive MPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group plc (MPH.L) and its competitors with MarketBeat's FREE daily newsletter.

MPH Stock News Headlines

Mereo BioPharma reports FY24 EPS (6c), consensus (5c)
Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
Mereo BioPharma initiated with an Outperform at LifeSci Capital
See More Headlines

MPH Stock Analysis - Frequently Asked Questions

Mereo BioPharma Group plc (MPH.L) (LON:MPH) announced its earnings results on Tuesday, September, 29th. The company reported ($105.00) earnings per share (EPS) for the quarter.

Shares of MPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group plc (MPH.L) investors own include Bausch Health Companies (BHC), Enanta Pharmaceuticals (ENTA), Advanced Micro Devices (AMD), American Tower (AMT), Bristol-Myers Squibb (BMY), Galaxy Digital (BRPHF) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
9/29/2020
Today
4/01/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:MPH
CIK
N/A
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
1.55
Book Value
GBX 7.20 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
£89.76 million
Optionable
Not Optionable
Beta
N/A
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (LON:MPH) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners